報價延遲最少15分鐘:2026/04/25 18:44 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.97 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.61/-0.64
|
|
企業價值
80.81M
|
| 資產負債 |
|
每股賬面淨值
0.44
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action. |
